An Open Label Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BAY 1841788 in Japanese Subjects With Metastatic Castration-resistant Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Darolutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 14 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 16 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 20 Feb 2015 New trial record